Market Research Report
C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||363124|
|Published||Content info||108 Pages
Delivery time: 1-2 business days
|C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020|
|Published: May 30, 2020||Content info: 108 Pages||
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 3, 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Respiratory, Cardiovascular, Hormonal Disorders, Immunology and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Multiple Sclerosis, Autoimmune Hepatitis, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Gastric Cancer, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Graves Diseases, Hashimoto Thyroiditis, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Liver Cancer, Lung Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polymyositis, Primary Sclerosing Cholangitis, Primary Sjogren's Syndrome, Prostate Cancer, Psoriasis, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Vasculitis.
Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.